Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC
Clinical trial NCT06001671 · COMPLETED
Trial details
- NCT number
- NCT06001671
- Sponsor
- Hunan Province Tumor Hospital
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-27
- Primary completion
- 2023-03-01
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.